Trial · NCT07492875
Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia
NCT07492875, Phase 3, Withdrawn, ImmunityBio, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia. Trials, record NCT07492875. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07492875
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia
- NCT number
- NCT07492875
- Status
- Withdrawn
- Phases
- Phase 3
- Enrollment
- 0 participants, actual
- Lead sponsor
- ImmunityBio, Inc.
- Conditions
- Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis, Lymphopenia, Immunoparalysis
- Interventions
- Nogapendekin alfa inbakicept (NAI), agenT-797
- First posted
- 2026-03-25
- Last updated
- 2026-05-08
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 28-day all-cause mortality | 30 days after the last dose of study drug | Up to Day 28 from randomization. (Participants lost to follow-up before Day 28 will be censored at their last known date alive; participants alive on Day 28 will be censored at Day 28). |
| Secondary | ALC count | From randomization through 28 days following randomization. | Absolute Lymphocyte Count |
| Secondary | Ventilator-Free days (VFD) through Day 28. | Through 28 days following randomization. | The number of days a participant is free from mechanical ventilation. |
| Secondary | Number of ICU free days through Day 28. | Through 28 days following randomization. | The number of days a participant is free from being in the Intensive Care Unit. |
| Secondary | Number of antibiotic free days through Day 28. | Through 28 days following randomization. | The number of days a participant is free from antibiotic treatment. |
| Secondary | Number of days alive and free of organ support through 28 days. | Through 28 days following randomization. | The number of days a participant is alive and does not require organ support. |
| Secondary | Time from first administration of study drug to ICU discharge. | From first study drug administration until ICU discharge, assessed up to 90 days; ICU discharge date documented from medical record (participants not discharged by Day 90 censored at Day 90; deaths prior to discharge counted as competing events). | The duration from the first dose of study drug until the participant is discharged from the Intensive Care Unit. |
| Secondary | Time from first administration of study drug to hospital discharge. | From first study drug administration until hospital discharge, assessed up to 90 days; hospital discharge date documented from medical record (participants not discharged by Day 90 censored at Day 90; deaths prior to discharge counted as competing events | The duration from the first dose of study drug until the participant is discharged from the hospital. |
| Secondary | Incidence of secondary infections through Day 28 and for the entire study. | From randomization through 90 days following randomization. | The occurrence rate of infections that develop after the start of study treatment. |
| Secondary | 90-day all-cause mortality. | Through 90 days following randomization. | Death from any cause. |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07492875
GET https://conductscience.org/api/trials/v1/NCT07492875/registered